Transcatheter Repair of Tricuspid Regurgitation With Edwards Cardioband TR System Post Market Study (TriBAND)

NCT ID: NCT03779490

Last Updated: 2023-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-24

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess the safety and the effectiveness of the Cardioband Tricuspid Reconstruction System.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the study is to assess the safety and the effectiveness of the Cardioband Tricuspid Reconstruction System. This is a multi-center, prospective, single-arm Post-Market Clinical Follow up Study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tricuspid Regurgitation Tricuspid Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcatheter Tricuspid Valve Repair

Transcatheter Tricuspid Valve Repair with Edwards Cardioband TR

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Eighteen (18) years of age or older
* Moderate or greater functional Tricuspid Regurgitation (TR)
* Patient is eligible to receive the Edwards Cardioband TR System per the current approved indications for use.

Exclusion Criteria

* Patients deemed anatomically unsuitable for the device by echocardiography
* Patients in whom transesophageal echocardiography (TEE) is contraindicated
* Previous tricuspid valve repair or replacement
* Severe aortic, mitral and / or pulmonic valve stenosis
* Severe aortic, mitral and / or pulmonic valve regurgitation
* Renal Insufficiency requiring dialysis or severe kidney renal disease
* Life expectancy of less than twelve months
* Patient is pregnant or lactating
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edwards Lifesciences

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Georg Nickenig, MD

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Bonn, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ulm University

Ulm, Bavaria, Germany

Site Status

Universitätsklinik der Ruhr-Universität Bochum

Bad Oeynhausen, North Rhine-Westphalia, Germany

Site Status

Herzzentrum der UniKlinik Köln

Cologne, North Rhine-Westphalia, Germany

Site Status

Charité - Universitätsmedizin Campus Mitte

Berlin, , Germany

Site Status

Berlin Charité-Benjamin Franklin

Berlin, , Germany

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Herzzentrum Universitätsklinik Dresden

Dresden, , Germany

Site Status

University Hospital Erlangen

Erlangen, , Germany

Site Status

Universitätsmedizin Göttingen, Herzzentrum Göttingen

Göttingen, , Germany

Site Status

Asklepios Klinik St. Georg

Hamburg, , Germany

Site Status

UKE Hamburg

Hamburg, , Germany

Site Status

Katholisches Marienkrankenhaus

Hamburg, , Germany

Site Status

Hospital Universitario Ramón y Cahal

Madrid, , Spain

Site Status

Universitätsspital Bern (Inselspital)

Bern, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany Spain Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Vernikouskaya I, Bertsche D, Rottbauer W, Rasche V. Deep learning-based framework for motion-compensated image fusion in catheterization procedures. Comput Med Imaging Graph. 2022 Jun;98:102069. doi: 10.1016/j.compmedimag.2022.102069. Epub 2022 May 13.

Reference Type DERIVED
PMID: 35576863 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-21

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The TRICURE First in Human Trial
NCT05126030 ACTIVE_NOT_RECRUITING NA
The TRICURE EFS Study
NCT06506942 RECRUITING NA
Edwards CLASP TR EFS
NCT03745313 COMPLETED NA